Raltegravir

Generic Name
Raltegravir
Brand Names
Isentress
Drug Type
Small Molecule
Chemical Formula
C20H21FN6O5
CAS Number
518048-05-0
Unique Ingredient Identifier
22VKV8053U
Background

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication

For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
Post-exposure prophylaxis for occupational exposure to HIV therapy
Clinical Trials
Related News

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

First Posted Date
2010-10-25
Last Posted Date
2018-10-09
Lead Sponsor
ViiV Healthcare
Target Recruit Count
828
Registration Number
NCT01227824
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Phase 4
Withdrawn
Conditions
Hepatitis C
HIV
Interventions
Drug: Atazanavir/ritonavir
Drug: raltegravir
First Posted Date
2010-10-21
Last Posted Date
2015-06-03
Lead Sponsor
University Hospital, Bonn
Registration Number
NCT01225705
Locations
🇩🇪

Private Practice Dupke, Carganico, Baumgarten, Berlin, Germany

🇩🇪

Department of Internal Medicine I, Bonn University, Bonn, Germany

🇩🇪

University of Frankfurt, Frankfurt / Main, Germany

and more 5 locations

Measurement of Plasma and Intracellular Concentrations of Raltegravir

Not Applicable
Completed
Conditions
HIV
Interventions
Drug: Raltegravir
First Posted Date
2010-10-05
Last Posted Date
2017-08-21
Lead Sponsor
University of Nebraska
Target Recruit Count
12
Registration Number
NCT01214486
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Phase 4
Completed
Conditions
HIV
Interventions
Drug: Truvada
Drug: Raltegravir
First Posted Date
2010-10-05
Last Posted Date
2016-02-08
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
103
Registration Number
NCT01214759
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)

Completed
Conditions
HIV-1 Infection
Interventions
Drug: Raltegravir
First Posted Date
2010-10-04
Last Posted Date
2016-05-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
451
Registration Number
NCT01213316

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

Phase 4
Conditions
HIV
Interventions
Drug: raltegravir
First Posted Date
2010-09-14
Last Posted Date
2010-09-14
Lead Sponsor
Shanghai Public Health Clinical Center
Target Recruit Count
50
Registration Number
NCT01201239
Locations
🇨🇳

Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

Pilot Study of Raltegravir Lipodystrophy IISP

Not Applicable
Conditions
HIV Infection
First Posted Date
2010-07-16
Last Posted Date
2012-05-18
Lead Sponsor
Southern California Institute for Research and Education
Target Recruit Count
30
Registration Number
NCT01164605
Locations
🇺🇸

VA Long Beach Healthcare System, Long Beach, California, United States

Pharmacokinetics of Low Dose Raltegravir

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: raltegravir
First Posted Date
2010-07-09
Last Posted Date
2020-07-17
Lead Sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Target Recruit Count
24
Registration Number
NCT01159132
Locations
🇹🇭

HIV-NAT, Bangkok, Thailand

Effects of Intensive cART During Acute/Early HIV Infection

First Posted Date
2010-07-01
Last Posted Date
2016-04-05
Lead Sponsor
University of Toronto
Target Recruit Count
32
Registration Number
NCT01154673
Locations
🇨🇦

University of Toronto, Toronto, Ontario, Canada

🇨🇦

Maple Leaf Medical Clinic, Toronto, Ontario, Canada

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

First Posted Date
2010-06-22
Last Posted Date
2021-08-13
Lead Sponsor
University of Hawaii
Target Recruit Count
80
Registration Number
NCT01147107
Locations
🇻🇳

Viet Tiep General Hospital, Hai Phong, Vietnam

🇻🇳

Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy